U.S. Physical Therapy, Inc. ("USPH" or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics, today reported results for the third quarter and nine months ended September 30, 2018.
For the quarter ended September 30, 2018, USPH’s Operating Results increased 34.9% to $8.1 million, or $0.64 per diluted share, as compared to $6.0 million, or $0.48 per diluted share, in the third quarter of 2017. For the nine months ended September 30, 2018, USPH’s Operating Results increased 22.6% to $24.5 million, or $1.93 per diluted share, as compared to $20.0 million, or $1.59 per diluted share, in the first nine months of 2017. Operating Results (as defined below), a non-generally accepted accounting principles (“non-GAAP”) measure, for the 2018 third quarter and first nine months results equal net income attributable to USPH shareholders. For the 2017 third quarter and first nine months, Operating Results is defined as net income attributable to USPH shareholders prior to charge for interest expense – mandatorily redeemable non-controlling interests – change in redemption value and charge for cost related to restatement of financials – legal and accounting, both charges net of tax.
For the quarter ended September 30, 2018, USPH’s net income attributable to its shareholders, in accordance with GAAP, was $8.1 million as compared to $5.2 million for the third quarter of 2017. Earnings per diluted share of $0.13 in the third quarter of 2018 compares to $0.41 per diluted share for the 2017 third quarter. For the nine months ended September 30, 2018, USPH’s net income attributable to its shareholders, in accordance with GAAP, was $24.5 million as compared to $14.9 million for the comparable period of 2017. Earnings per diluted share of $0.88 in the 2018 first nine months compares to $1.19 per diluted share for the 2017 first nine months. For both periods of 2018, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not included in net income but rather charged directly to retained earnings, but is included in the earnings per basic and diluted share calculation. See the schedule on page 13 for a computation of diluted earnings per share and a reconciliation of net income attributable to USPH shareholders to Operating Results.
Third Quarter 2018 Compared to Third Quarter 2017
First Nine Months 2018 Compared to First Nine Months 2017
Other Financial Measures
For the third quarter of 2018 the Company's Adjusted EBITDA increased by 14.1% to $15.6 million from $13.7 million in the comparable 2017 quarter. For the first nine months of 2018 the Company's Adjusted EBITDA increased by 8.4% to $46.6 million from $43.0 million in the comparable 2017 period. See definition and explanation of Adjusted EBITDA in the schedule on pages 12 and 13.
Management Raises 2018 Earnings Guidance
The Company is again raising earnings guidance for the year 2018. Management currently expects the Company’s Operating Results for the year 2018 to be in the range of $31.7 million to $32.7 million or $2.50 to $2.57 per share. The Company’s original earnings guidance, issued in March 2018, was for Operating Results of $29.5 million to $30.9 million or $2.34 to $2.44 per share. In August the guidance for Operating results was increased to $31.1 million to $32.3 million or $2.45 to $2.55 per share. Please note that the earnings guidance represents projected Operating Results from existing operations but excludes future acquisitions. The annual guidance figures may not be updated unless there is a material development that causes management to believe that Operating Results will be significantly outside the given range.
Management’s Comments
Chris Reading, Chief Executive Officer, said, “I am extremely proud of our entire team of clinicians, partners and support staff for their efforts and results thus far this year. Summer is a traditionally slower time for us and yet by almost every measure we were able to produce meaningful improvement. We will continue our focused efforts to finish 2018 in a strong fashion while we work to support our partnerships and attract new opportunities in physical therapy as well as our industrial injury prevention services business.”
Larry McAfee, Chief Financial Officer, noted, “Despite having made two acquisitions in the past 12 months for total consideration of $16.4 million and having paid more than $11.3 million in dividends to shareholders, the Company’s net debt (debt minus cash) was reduced from $45.3 million as of September 30, 2017 down to $27.2 million as of September 30, 2018. Net cash flow from operations remains strong and the average age of the Company’s receivables at the end of the quarter was approximately 38 days.”
U.S. Physical Therapy Declares Quarterly Dividend
The fourth quarterly dividend for 2018 of $0.23 per share will be paid on December 7, 2018 to shareholders of record as of November 9, 2018. U.S. Physical Therapy began paying quarterly dividends in 2011 and has increased the dividend amount every year since.
Redeemable Non-Controlling Interests
Effective December 31, 2017, the Company entered into amendments to its acquired limited partnership agreements replacing the mandatory redemption feature. No monetary consideration was paid to the partners to amend the agreements. The amended Partnership Agreements provide that, upon certain events, the Company has a call right (the “Call Right”) and the selling entity has a put right (the “Put Right”) for the purchase and sale of the limited partnership interest held by the partner. Once the terms are triggered, the Put Right and the Call Right do not expire, even upon an individual partner’s death, and contain no mandatory redemption feature. The purchase price of the partner’s limited partnership interest upon the exercise of either the Put Right or the Call Right is calculated per the original terms of the respective agreements. The Company accounted for the amendment of its Partnership Agreements as an extinguishment of the outstanding Seller Entity Interests classified as liabilities through the issuance of new Seller Entity Interests classified in temporary equity. Pursuant to ASC 470-50-40-2, the Company removed the outstanding liability-classified Seller Entity Interests at their carrying amounts and recognized the new temporary-equity-classified Seller Entity Interests at their fair value. In summary, the redemption values of the mandatorily redeemable non-controlling interest (previously classified as liabilities) were reclassified as redeemable non-controlling interest (temporary equity) on the December 31, 2017 consolidated balance sheet. For 2018, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is not charged to net income but is charged to retained earnings and is included in the earnings per basic and diluted share calculation.
Third Quarter 2018 Conference Call
U.S. Physical Therapy's Management will host a conference call at 10:30 a.m. Eastern Time, 9:30 a.m. Central Time, on November 1, 2018 to discuss the Company's Quarter and Nine Months Ended September 30, 2018 results. Interested parties may participate in the call by dialing 1-888-335-5539 or 973-582-2857 and entering reservation number 5977355 approximately 10 minutes before the call is scheduled to begin. To listen to the live call via web-cast, go to the Company's website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. The conference call will be archived and can be accessed until February 2, 2019.
Forward-Looking Statements
This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this press release. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. operates 588 outpatient physical therapy clinics in 42 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 26 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention, rehabilitation, ergonomic assessments and performance optimization.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES | ||||||||||||||||
CONSOLIDATED STATEMENTS OF NET INCOME | ||||||||||||||||
(IN THOUSANDS, EXCEPT PER SHARE DATA) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, |
September 30, |
September 30, |
September 30, |
|||||||||||||
Net patient revenues | $ | 103,354 | $ | 96,273 | $ | 309,895 | $ | 287,584 | ||||||||
Other revenues | 9,768 | 6,759 | 26,667 | 17,264 | ||||||||||||
Net revenues | 113,122 | 103,032 | 336,562 | 304,848 | ||||||||||||
Operating costs: | ||||||||||||||||
Salaries and related costs | 64,524 | 60,306 | 191,410 | 174,912 | ||||||||||||
Rent, supplies, contract labor and other | 21,654 | 20,600 | 65,598 | 60,720 | ||||||||||||
Provision for doubtful accounts | 890 | 930 | 3,102 | 2,716 | ||||||||||||
Closure costs | (22 | ) | 4 | 8 | 27 | |||||||||||
Total operating costs | 87,046 | 81,840 | 260,118 | 238,375 | ||||||||||||
Gross profit | 26,076 | 21,192 | 76,444 | 66,473 | ||||||||||||
Corporate office costs | 10,643 | 8,304 | 30,934 | 25,707 | ||||||||||||
Operating income | 15,433 | 12,888 | 45,510 | 40,766 | ||||||||||||
Interest and other income, net | 16 | 11 | 70 | 58 | ||||||||||||
Interest expense: | ||||||||||||||||
Mandatorily redeemable non-controlling interests - change in redemption value | - | (1,247 | ) | - | (7,839 | ) | ||||||||||
Mandatorily redeemable non-controlling interests - earnings allocable | - | (1,285 | ) | - | (4,366 | ) | ||||||||||
Debt and other | (579 | ) | (641 | ) | (1,677 | ) | (1,572 | ) | ||||||||
Total interest expense | (579 | ) | (3,173 | ) | (1,677 | ) | (13,777 | ) | ||||||||
Income before taxes | 14,870 | 9,726 | 43,903 | 27,047 | ||||||||||||
Provision for income taxes | 2,991 | 3,132 | 8,734 | 8,029 | ||||||||||||
Net income | 11,879 | 6,594 | 35,169 | 19,018 | ||||||||||||
Less: net income attributable to non-controlling interests | (3,777 | ) | (1,444 | ) | (10,704 | ) | (4,111 | ) | ||||||||
Net income attributable to USPH shareholders | $ | 8,102 | $ | 5,150 | $ | 24,465 | $ | 14,907 | ||||||||
Basic and diluted earnings per share attributable to USPH shareholders | $ | 0.13 | $ | 0.41 | $ | 0.88 | $ | 1.19 | ||||||||
Shares used in computation - basic and diluted | 12,685 | 12,581 | 12,660 | 12,563 | ||||||||||||
Dividends declared per common share | $ | 0.23 | $ | 0.20 | $ | 0.69 | $ | 0.60 | ||||||||
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(IN THOUSANDS, EXCEPT SHARE DATA) | ||||||||
September 30, |
December 31, |
|||||||
ASSETS | (unaudited) | |||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 32,241 | $ | 21,933 | ||||
Patient accounts receivable, less allowance for doubtful accounts of $2,690 and $2,273, respectively | 43,899 | 44,707 | ||||||
Accounts receivable - other | 9,609 | 5,655 | ||||||
Other current assets | 4,908 | 4,786 | ||||||
Total current assets | 90,657 | 77,081 | ||||||
Fixed assets: | ||||||||
Furniture and equipment | 52,473 | 51,100 | ||||||
Leasehold improvements | 31,101 | 29,760 | ||||||
Fixed assets, gross | 83,574 | 80,860 | ||||||
Less accumulated depreciation and amortization | 63,608 | 60,475 | ||||||
Fixed assets, net | 19,966 | 20,385 | ||||||
Goodwill | 293,630 | 271,338 | ||||||
Other identifiable intangible assets, net | 49,311 | 48,954 | ||||||
Other assets | 1,405 | 1,224 | ||||||
Total assets | $ | 454,969 | $ | 418,982 | ||||
LIABILITIES, REDEEMABLE NON-CONTROLLING INTERESTS, USPH SHAREHOLDERS' EQUITY AND NON-CONTROLLING INTERESTS | ||||||||
Current liabilities: | ||||||||
Accounts payable - trade | $ | 2,067 | $ | 2,165 | ||||
Accrued expenses | 40,128 | 33,342 | ||||||
Current portion of notes payable | 4,769 | 4,044 | ||||||
Total current liabilities | 46,964 | 39,551 | ||||||
Notes payable, net of current portion | 659 | 2,728 | ||||||
Revolving line of credit | 54,000 | 54,000 | ||||||
Mandatorily redeemable non-controlling interests | - | 327 | ||||||
Deferred taxes | 8,643 | 10,875 | ||||||
Deferred rent | 1,864 | 2,116 | ||||||
Other long-term liabilities | 835 | 743 | ||||||
Total liabilities | 112,965 | 110,340 | ||||||
Redeemable non-controlling interests | 128,906 | 102,572 | ||||||
Commitments and contingencies | ||||||||
U.S. Physical Therapy, Inc. ("USPH") shareholders' equity: | ||||||||
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding | - | - | ||||||
Common stock, $.01 par value, 20,000,000 shares authorized, 14,899,409 and 14,809,299 shares issued, respectively | 149 | 148 | ||||||
Additional paid-in capital | 78,542 | 73,940 | ||||||
Retained earnings | 164,821 | 162,406 | ||||||
Treasury stock at cost, 2,214,737 shares | (31,628 | ) | (31,628 | ) | ||||
Total USPH shareholders' equity | 211,884 | 204,866 | ||||||
Non-controlling interests | 1,214 | 1,204 | ||||||
Total USPH shareholders' equity and non-controlling interests | 213,098 | 206,070 | ||||||
Total liabilities, redeemable non-controlling interests, USPH shareholders' equity and non-controlling interests | $ | 454,969 | $ | 418,982 | ||||
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(IN THOUSANDS, EXCEPT PER SHARE DATA) | ||||||||
(unaudited) | ||||||||
Nine Months Ended | ||||||||
September 30, |
September 30, |
|||||||
OPERATING ACTIVITIES | ||||||||
Net income including non-controlling interests | $ | 35,169 | $ | 19,018 | ||||
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 7,335 | 7,269 | ||||||
Provision for doubtful accounts | 3,102 | 2,716 | ||||||
Equity-based awards compensation expense | 4,453 | 3,410 | ||||||
Loss on sale of fixed assets | 128 | 83 | ||||||
Deferred income taxes | (3,099 | ) | 291 | |||||
Changes in operating assets and liabilities: | ||||||||
Increase in patient accounts receivable | (1,092 | ) | (1,914 | ) | ||||
Increase in accounts receivable - other | (3,954 | ) | (4,736 | ) | ||||
Decrease (increase) in other assets | 233 | (787 | ) | |||||
Increase in accounts payable and accrued expenses | 9,742 | 8,126 | ||||||
Increase in mandatorily redeemable non-controlling interests | - | 7,069 | ||||||
Increase in other liabilities | 1,988 | 286 | ||||||
Net cash provided by operating activities | 54,005 | 40,831 | ||||||
INVESTING ACTIVITIES | ||||||||
Purchase of fixed assets | (5,307 | ) | (5,576 | ) | ||||
Purchase of businesses, net of cash acquired | (16,303 | ) | (33,740 | ) | ||||
Purchase of non-controlling interest | (272 | ) | - | |||||
Proceeds on sale of fixed assets | 2 | 67 | ||||||
Net cash used in investing activities | (21,880 | ) | (39,249 | ) | ||||
FINANCING ACTIVITIES | ||||||||
Distributions to non-controlling interests, permanent and temporary equity | (10,470 | ) | (3,698 | ) | ||||
Cash dividends paid to shareholders | (8,746 | ) | (7,547 | ) | ||||
Proceeds from revolving line of credit | 79,000 | 63,000 | ||||||
Payments on revolving line of credit | (79,000 | ) | (53,000 | ) | ||||
Payments to settle mandatorily redeemable non-controlling interests | (265 | ) | (2,230 | ) | ||||
Principal payments on notes payable | (2,294 | ) | (776 | ) | ||||
Other | (42 | ) | 40 | |||||
Net (cash used in) provided by financing activities | (21,817 | ) | (4,211 | ) | ||||
Net increase in cash and cash equivalents | 10,308 | (2,629 | ) | |||||
Cash and cash equivalents - beginning of period | 21,933 | 20,047 | ||||||
Cash and cash equivalents - end of period | $ | 32,241 | $ | 17,418 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||||||||
Cash paid during the period for: | ||||||||
Income taxes | $ | 8,957 | $ | 8,059 | ||||
Interest | $ | 1,705 | $ | 1,616 | ||||
Non-cash investing and financing transactions during the period: | ||||||||
Purchase of business - seller financing portion | $ | 950 | $ | 1,650 | ||||
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES |
OPERATING RESULTS AND ADJUSTED EBITDA |
(IN THOUSANDS, EXCEPT PER SHARE DATA) |
(unaudited) |
The following tables provide a detail of the diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Operating Results and Adjusted EBITDA. Management believes providing Operating Results and Adjusted EBITDA to investors is useful information for comparing the Company's period-to-period results.
For 2018, Operating Results equal net income attributable to USPH shareholders and, in accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, charged directly to retained earnings is included in the earnings per diluted share calculation. For the 2017 first nine months, Operating Results, a non-generally accepted accounting principles (“non-GAAP”) measure, is defined as net income attributable to common shareholders prior to interest expense – mandatorily redeemable non-controlling interests – change in redemption value and charge for cost related to restatement of financials – legal and accounting, both charges net of tax.
Operating Results for the two periods are comparable, however, the calculations differ. Management uses Operating Results, which eliminates this current non-cash item that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have mandatorily redeemable instruments and therefore have different liability and equity structures.
Adjusted EBITDA is defined as earnings before interest income, interest expense – mandatorily redeemable non-controlling interests – change in redemption value, interest expense – debt and other, taxes, depreciation, amortization and equity-based awards compensation expense. Management believes reporting Adjusted EBITDA is useful information for investors in comparing the Company’s period-to-period results as well as comparing with similar businesses which report adjusted EBITDA as defined by their company.
Operating Results and Adjusted EBITDA are not measures of financial performance under GAAP. Adjusted EBITDA and Adjusted Net Income should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.
Three Months Ended |
Nine Months Ended |
|||||||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||||||
Computation of earnings per share - USPH shareholders | ||||||||||||||||
Net income attributable to USPH shareholders | $ | 8,102 | $ | 5,150 | $ | 24,465 | $ | 14,907 | ||||||||
Charges to retained earnings: | ||||||||||||||||
Revaluation of redeemable non-controlling interest | $ | (8,680 | ) | $ | - | (18,105 | ) | - | ||||||||
Tax effect at statutory rate (federal and state) of 26.25% | 2,279 | - | 4,753 | - | ||||||||||||
$ | 1,701 | $ | 5,150 | $ | 11,113 | $ | 14,907 | |||||||||
Basic and diluted per share | $ | 0.13 | $ | 0.41 | $ | 0.88 | $ | 1.19 | ||||||||
Adjustments: | ||||||||||||||||
Interest expense MRNCI * - change in redemption value | - | 1,247 | - | 7,839 | ||||||||||||
Cost related to restatement of financials - legal and accounting | - | 158 | - | 470 | ||||||||||||
Revaluation of redeemable non-controlling interest | 8,680 | - | 18,105 | - | ||||||||||||
Tax effect at statutory rate (federal and state) of 26.25% and 39.25%, respectively | (2,279 | ) | (551 | ) | (4,753 | ) | (3,261 | ) | ||||||||
Operating results | $ | 8,102 | $ | 6,004 | $ | 24,465 | $ | 19,955 | ||||||||
Basic and diluted operating results per share | $ | 0.64 | $ | 0.48 | $ | 1.93 | $ | 1.59 | ||||||||
Shares used in computation: | ||||||||||||||||
Basic and diluted | 12,685 | 12,581 | 12,660 | 12,563 | ||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||||||
Net income attributable to USPH shareholders | $ | 8,102 | $ | 5,150 | $ | 24,465 | $ | 14,907 | ||||||||
Adjustments: | ||||||||||||||||
Depreciation and amortization | 2,469 | 2,480 | 7,335 | 7,269 | ||||||||||||
Interest income | (16 | ) | (11 | ) | (70 | ) | (58 | ) | ||||||||
Interest expense MRNCI * - change in redemption value | - | 1,247 | - | 7,839 | ||||||||||||
Interest expense - debt and other | 579 | 641 | 1,677 | 1,572 | ||||||||||||
Provision for income taxes | 2,991 | 3,132 | 8,734 | 8,029 | ||||||||||||
Equity-based awards compensation expense | 1,516 | 1,065 | 4,453 | 3,410 | ||||||||||||
Adjusted EBITDA | $ | 15,641 | $ | 13,704 | $ | 46,594 | $ | 42,968 | ||||||||
* Mandatorily redeemable non-controlling interest |
||||||||||||||||
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES | ||
RECAP OF CLINIC COUNT | ||
Date | Number of Clinics | |
March 31, 2017 | 558 | |
June 30, 2017 | 566 | |
September 30, 2017 | 569 | |
December 31, 2017 | 578 | |
March 31, 2018 | 580 | |
June 30, 2018 | 581 | |
September 30, 2018 | 588 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005150/en/
U.S. Physical Therapy, Inc.
Larry McAfee, (713) 297-7000
Chief
Financial Officer
or
Chris Reading, (713) 297-7000
Chief
Executive Officer
or
Three Part Advisors
Joe Noyons,
(817) 778-8424